COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 9843.T

Comparison against 9843.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

166.62

Increased from previous period

OCF/share of $3–5 – Solid range. Seth Klarman would ensure the company can fund growth and dividends internally.

Free Cash Flow per Share

143.69

Increased from previous period

FCF/share $2–3 – Adequate. Seth Klarman might see if incremental growth can lift free cash flow further.

Capex-to-Operating Cash Flow

13.76%

Increased from previous period

Capex/OCF ratio of 13.76% while 9843.T is zero. Bruce Berkowitz would question if the competitor’s spending is unsustainably minimal.

Income Quality Ratio (OCF / Net Income)

3.04

Increased from previous period

Ratio of 3.04 while 9843.T is zero. Bruce Berkowitz might see a small but meaningful advantage in real cash coverage.

Operating Cash Flow-to-Sales Ratio

13.59%

Increased from previous period

OCF-to-sales 15–25% – Good. Seth Klarman would check if there is still room to optimize working capital.

Select Chart Metric:

3349.T Cash Flow Analysis - Compare Against 9843.T

Comparison against 9843.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

166.62

Increased from previous period

OCF/share of $3–5 – Solid range. Seth Klarman would ensure the company can fund growth and dividends internally.

Free Cash Flow per Share

143.69

Increased from previous period

FCF/share $2–3 – Adequate. Seth Klarman might see if incremental growth can lift free cash flow further.

Capex-to-Operating Cash Flow

13.76%

Increased from previous period

Capex/OCF ratio of 13.76% while 9843.T is zero. Bruce Berkowitz would question if the competitor’s spending is unsustainably minimal.

Income Quality Ratio (OCF / Net Income)

3.04

Increased from previous period

Ratio of 3.04 while 9843.T is zero. Bruce Berkowitz might see a small but meaningful advantage in real cash coverage.

Operating Cash Flow-to-Sales Ratio

13.59%

Increased from previous period

OCF-to-sales 15–25% – Good. Seth Klarman would check if there is still room to optimize working capital.

Select Chart Metric: